Experience

Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 865,963 shares of common stock for an aggregate price to the public of approximately $143.75 million,…

Davis Polk advised the joint book-running managers and representatives of the initial purchasers in connection with a Rule 144A offering by 1Life Healthcare, Inc. of $275 million…

Davis Polk advised the representatives of the underwriters in connection with the $70 million follow-on public offering of 5,000,000 shares of common stock of TransMedics Group, Inc…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by DENTSPLY SIRONA Inc. of $750 million aggregate principal amount of…

Davis Polk advised the representatives of the underwriters in connection with the $60 million SEC-registered follow-on offering of ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised the joint book-running managers in connection with a $325 million SEC-registered common stock offering by Turning Point Therapeutics, Inc. The common stock is listed…

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which included the exercise in full by the underwriters of their option to…

Davis Polk advised the underwriters in connection with the public offering of 2,369,668 shares of common stock of Insulet Corporation. The offering resulted in approximately $500…

Davis Polk the initial purchasers in connection with a Rule 144A offering by Cantel Medical Corp. of $140 million principal amount of 3.250% convertible senior notes due 2025. Cantel’s…

Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by Alector, Inc. of shares of its common stock for up to a maximum offering price of …